Top doctors raised concerns about domestically made drugs, saying Beijing’s effort to lower costs is sacrificing quality.

Adding camrelizumab and rivoceranib to TACE improved PFS in patients with unresectable HCC in a phase 2 trial.

Atara Biotherapeutics said the U.S. Food and Drug Administration placed a clinical hold on its active investigational new drug applications. The biotechnology company said the FDA put a hold on ...

"China has historically suffered greatly from the harms of drugs, which gives us a profound understanding and resolute attitude toward drug issues, particularly concerning new psychoactive ...

China has become a key piece of Foresite Capital’s investment and company formation strategy. During the J.P. Morgan Healthcare Conference, Managing Director Michael Rome shared his thoughts on why ...

In an effort to safeguard fair market competition and protect consumer interests, the State Council's anti-monopoly ...

A Chinese court's decision to revise the ruling in a drug case involving a former associate chemistry professor — dubbed the "Chinese version of Breaking Bad" — reflects the country's commitment to ...

The biotech said it has dosed the first participant in a Phase 3 study of its in vivo gene editing treatment. Elsewhere, the FDA imposed a hold on Atara and lifted another on Amylyx.

It’s always a good sign when a couple of big deals are announced right before the conference, and this year we saw a doozie ...

The revision of labeling for products approved or submitted for approval under an abbreviated new drug application (ANDA) depends on the labeling of the listed drug referenced in the ANDA.

The younger Maltz later headed the New York Drug Enforcement Task Force ... administration for not doing more to target the drug cartels and Chinese precursor chemical makers responsible for ...